Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

This study is testing a four-drug combination therapy for newly diagnosed multiple myeloma (a blood cancer). The combination includes carfilzomib, lenalidomide, dexamethasone (a standard regimen), plus a newer drug called belantamab mafodotin, which targets a protein on myeloma cells. Researchers want to see if adding this drug improves outcomes. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with multiple myeloma - You are in reasonably good health (able to care for yourself) - Your heart, kidneys, liver, and blood counts are within acceptable ranges - You have not received prior treatment for multiple myeloma **You may NOT be eligible if...** - You have previously been treated for multiple myeloma - You have significant heart problems (low pumping function) - You are under 18 years old - You have poor organ function Talk to your doctor to see if this trial is right for you.